Keio University · Medicine
Professor Atsuo Nakagawa's research lab focuses on psychopharmacology and clinical psychiatry, with a primary emphasis on antidepressant treatment outcomes, suicide prevention, and the impact of comorbid psychiatric conditions on mental health. The lab investigates the real-world effectiveness, tolerability, and safety of newer antidepressants such as milnacipran, particularly in diverse populations and clinical contexts. It also explores disparities in clinical decision-making across cultures, highlighting how sociocultural factors and clinical workload influence treatment choices despite standardized guidelines.
Figures are computed from collected data and may differ slightly.
UMIN Clinical Trials Registry identifier: UMIN000001218.
Article Abstract Objective: We examined the relationship of increasing prescription volume of newer antidepressants, introduced in Japan in 1999, to national rates of suicide. Method: The relationship between annual changes in rates of suicide (obtained from the Japanese Ministry of Health, Labor, and Welfare Vital Statistics Database) and prescription volume of the newer antidepressants paroxetine, fluvoxamine, and milnacipran (obtained from the database of IMS Japan K.K.), stratified by gender
Currently, there is inadequate evidence to conclude whether milnacipran is superior, inferior or the same as other antidepressive agents in terms of efficacy, acceptability and tolerability in the acute phase treatment of major depression. However, there is some evidence in favour of milnacipran over TCAs in terms of dropouts due to adverse events (acceptability) and the rates of experiencing adverse events (tolerability). Information about other clinically meaningful outcomes such as cost-effec
University Hospital Medical Information Network Clinical Trials Registry: UMIN000009242; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010852 (Archived by WebCite at http://www.webcitation. org/729VkpyYL).
Comorbid Cluster B personality disorder appears to exert a stronger influence on suicidality than comorbid anxiety disorder in persons with bipolar disorder. Assessment of suicide risk in patients with bipolar disorder should include evaluation and treatment of Cluster B psychopathology.
Differences were found between the treatment selections of early-career psychiatrists in Japan and the USA, despite comparable guidelines and postgraduate training. The results suggest that the gap between guidelines and practice may also be shaped by physician workload, attitudes toward side-effects, and the sociocultural contexts in which clinical decisions are made.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: (1) To determine the efficacy of milnacipran in comparison with other anti‐depressive agents in alleviating the acute symptoms of depression. (2) To review acceptability of treatment with milnacipran in comparison with other anti‐depressive agents. (3) To investigate the adverse effects of milnacipran in comparison with other anti‐depressive agents.
<b>Objective:</b> Although family involvement in the treatment of obsessive-compulsive disorder (OCD) produces a reduction in OCD symptoms and has significant effects on global functioning, few studies have focused on family intervention as part of OCD treatment in Japan. This study aims to examine the feasibility and efficacy of the family-based exposure and response prevention (FERP) program for adult patients with OCD and their family members. <b>Design:</b> Randomized controlled pilot study.
Open papers in the app to read, cite, and organize with AI.
